Drug Trial Radar · NCT01414855
A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)
Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
100
Actual
Start
Aug 31, 2011
Primary completion
Dec 31, 2013
Study completion Dec 23, 2016
Sponsor
- Lead sponsor
- Genentech, Inc.Roche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Aug 11, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This open-label, multicenter study will evaluate the efficacy and safety of obinutuzumab \[RO5072759 (GA101)\] in combination with CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) chemotherapy in patients with advanced diffuse large B-cell lymphoma. Patients will receive 8 cycles of obinutuzumab (1000 mg intravenously on Day 1 of each 21-day cycle, during Cycle 1 obinutuzumab will also be infused on Days 8 and 15) in combination with CHOP chemotherapy on Day 1 of cycles 1 to 6. A substudy will investigate the drug-drug interaction of obinutuzumab with CHOP chemotherapy agents. For the substudy, an additional cohort of approximately 15 patients are planned to be enrolled at a subset of investigational sites.
Conditions
- Lymphoma, B-Cell
Interventions
obinutuzumabDrug
1000 mg intravenously on Day 1 of each 21-day cycle, 8 cycles; during Cycle 1 administration also on Days 8 and 15.
cyclophosphamideDrug
750 mg/m\^2 intravenous (IV), Day 1 of each 21-day cycle, 6 cycles.
doxorubicinDrug
50 mg/m\^2 IV, Day 1 of each 21-cycle, 6 cycles.
prednisoneDrug
100 mg/day, Days 1 through 5 of each 21-day cycle, 6 cycles.
vincristineDrug
1.4 mg/m\^2 IV, Day 1 of each 21-day cycle, 6 cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete Response (CR) Rate as Assessed by the Investigator at the End of TreatmentTime frame: From the first dose of study treatment to end of treatment response assessment (approximately 228 to 258 days)
- Overall Response Rate (ORR) as Assessed by the Investigator at the End of TreatmentTime frame: From the first dose of study treatment to end of treatment response assessment (approximately 228 to 258 days)
Locations
38 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
cCare
Encinitas, California
University of Colorado Cancer Center Department of Hematology
Aurora, Colorado
Rocky Mountain Cancer Ctr - Denver (Williams)
Denver, Colorado
Norwalk Hospital
Norwalk, Connecticut
Florida Cancer Specialists; Department of Oncology
Fort Myers, Florida
Florida Cancer Specialists; Saint Petersburg
St. Petersburg, Florida
Northwest Georgia Oncology Centers PC - Marietta
Marietta, Georgia
Kootenai Medical Center
Coeur d'Alene, Idaho
Northwestern University; Robert H. Lurie Comp Can Ctr
Chicago, Illinois
Onc Hem Assoc of Central IL
Peoria, Illinois
McFarland Clinic
Ames, Iowa
Jewish Cancer Care
Louisville, Kentucky
University of Massachusetts Medical School
Worcester, Massachusetts
University of Michigan
Ann Arbor, Michigan
MT Cancer Inst Fndtn; MT Can Spec
Missoula, Montana
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
MSKCC at Basking Ridge
Basking Ridge, New Jersey
Hackensack University Medical Center
Hackensack, New Jersey
San Juan Oncology Associates
Farmington, New Mexico
Memorial Sloan-Kettering; Cancer Center
Commack, New York
Memorial Sloan Kettering Cancer Center
New York, New York
MSKCC at Mercy Med Ctr
Rockville Centre, New York
MSKCC at Sleepy Hollow
Sleepy Hollow, New York
Emerywood Hematology and Onc
High Point, North Carolina
Willamette Valley Cancer Insitute and Research Center
Springfield, Oregon
Medical University of SC (MUSC)
Charleston, South Carolina
SCRI-Tennessee Oncology
Nashville, Tennessee
Onc & Hem Assoc; USO Cent Pharm
Fort Worth, Texas
MD Anderson Cancer Center Department of Lymphoma & Myeloma
Houston, Texas
Methodist Hospital Research Institute
Houston, Texas
Cancer Therapy & Research Center
San Antonio, Texas
USO - Tyler Cancer Ctr
Tyler, Texas
Blue Ridge Cancer Care - Roanoke
Roanoke, Virginia
Medical Oncology Associates
Spokane, Washington
Northwest Cancer Specialists - Vancouver
Vancouver, Washington
Yakima Valley Memorial Hospital/North Star Lodge
Yakima, Washington
Aurora Bay Care Medical Center
Green Bay, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.